

Adult COVID-19 Vaccine Dosing Quick Reference Guide

Moderna, Pfizer-BioNTech, and Novavax COVID-19 Vaccine Products



Moderna COVID-19 Vaccine Products 2025-2026 Formula	Pfizer-BioNTech COVID-19 Vaccine Products 2025-2026 Formula	Novavax COVID-19 Vaccine Products 2025-2026 Formula
Spikevax (blue label) mNEXSPIKE (teal label)	Comirnaty (gray label)	Nuvaxovid (dark cyan label)
 0.5 ml single-dose prefilled syringe	 0.3 ml single-dose prefilled syringe	 0.5 ml single-dose prefilled syringe

The diagram illustrates the recommended COVID-19 vaccine schedules for two groups: Unvaccinated and Previously Vaccinated with Prior Formulation.

Unvaccinated: This group is recommended to receive 1 dose of any of the following COVID-19 vaccines: Spikevax (blue label), mNEXSPIKE (teal label), Comirnaty (gray label), or Nuvaxovid (dark cyan label).

Previously Vaccinated with Prior Formulation: This group is recommended to receive 1 or more doses of any COVID vaccine, NOT including 2025–2026 COVID vaccine. The diagram shows four options, each requiring a wait time after the last dose before receiving the next dose:

- Spikevax (blue label):** 1 dose, wait ≥8 weeks after last dose.
- mNEXSPIKE (teal label):** 1 dose, wait >12 weeks after last dose.
- Comirnaty (gray label):** 1 dose, wait ≥8 weeks after last dose.
- Nuvaxovid (dark cyan label):** 1 dose, wait ≥8 weeks after last dose.

The flowchart is divided into two main sections: 'Unvaccinated^a' and 'Previously Vaccinated with Prior Formulation'.

Unvaccinated^a: This section leads to a box containing four vaccine options: Spikevax (blue label), mNEXSPIKE (teal label), Comirnaty (gray label), and Nuvaxovid (dark cyan label). Each vaccine option has a sequence of 'Dose 1' and 'Dose 2', with a requirement of '>6 months after last dose^b' between the two doses.

Previously Vaccinated with Prior Formulation: This section starts with a box stating '1 or more doses of any COVID vaccine, NOT including 2025–2026 COVID vaccine'. It then leads to a box with the same four vaccine options. For each vaccine, the schedule is 'Dose 1' followed by 'Dose 2', with specific time intervals between doses: '>8 weeks after last dose' for Spikevax and Comirnaty, and '>12 weeks after last dose' for mNEXSPIKE and Nuvaxovid. A final requirement of '>6 months after last dose^b' is shown after Dose 2.

Footnotes:

- ^a Includes individuals who received a COVID-19 vaccine in 2020 or 2021.
- ^b For individuals who received a COVID-19 vaccine in 2020 or 2021, the time interval between doses should be at least 6 months.

Previously received vaccine(s)

Unvaccinated^a

Previously Vaccinated with Prior Formulations

Recommended 2025–2026 vaccine

Additional doses may be administered

The flowchart is organized into two main columns: 'Unvaccinated^a' and 'Previously Vaccinated with Prior Formulations'. The 'Unvaccinated' column shows three vaccine options: Spikevax (blue label) OR mNEXSPIKE (teal label), Comirnaty (gray label), and Nuvaxovid (dark cyan label). Each option has a sequence of four doses with specific intervals: 4 weeks after dose 1, 3 weeks after dose 1, 3 weeks after dose 1, and ≥4 weeks after dose 2. The 'Previously Vaccinated' column is further divided into sub-groups based on the number and type of previous doses. For example, '1 dose any Moderna' leads to a sequence of four doses with intervals of 4 weeks, ≥4 weeks, ≥4 weeks, and 6 months. '3 or more doses any Moderna or any Pfizer NOT including at least 1 dose any 2025–2026 COVID vaccine' leads to a sequence of three doses with intervals of ≥8 weeks after the last dose, 6 months after dose 3^b, and 6 months after dose 3^b. The flowchart uses color-coded boxes and arrows to guide the user through the recommended schedule for each scenario. A red box at the bottom indicates that additional doses may be administered.

b Moderna (Spikevax), Novavax, or Pfizer-BioNTech): Minimum interval 2 months after last 2025–2026 Dose; Moderna (mNexspike): Minimum interval 3 months after last 2025–2026 Dose

Note: Routine administration of all age-appropriate doses of vaccines simultaneously, also known as coadministration, is acceptable for adults if there are no contraindications at the time of the healthcare visit.